Fabien C Lamaze
Overview
Explore the profile of Fabien C Lamaze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Driussi A, Lamaze F, Kordahi M, Armero V, Goudreault N, Orain M, et al.
Mod Pathol
. 2025 Feb;
:100744.
PMID: 40020968
The implementation of lung cancer screening programs across the world has drawn considerable attention to improve early-stage lung cancer detection and prognostication. Several blood-based assays detecting circulating tumor DNA (ctDNA)...
2.
Kordahi M, Gagne A, Abolfathi H, Orain M, Couture C, Desmeules P, et al.
Am J Surg Pathol
. 2024 Dec;
49(2):169-175.
PMID: 39716866
Intraoperative frozen section (FS) examination of oncologic surgical specimens is frequently performed to ensure complete surgical resection. Data on the gross evaluation of surgical margins are limited. We recently published...
3.
Boullier C, Lamaze F, Haince J, Bux R, Orain M, Zheng J, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335151
Background/objectives: Pulmonary neuroendocrine neoplasms (NENs) account for 20% of malignant lung tumors. Their management is challenging due to their diverse clinical features and aggressive nature. Currently, metabolomics offers a range...
4.
Bosse Y, Dasgupta A, Abadier M, Guthrie V, Song F, Armero V, et al.
Cancer Lett
. 2024 May;
594:216984.
PMID: 38797230
Background: Circulating tumor DNA (ctDNA) positivity at diagnosis, which is associated with worse outcomes in multiple solid tumors including stage I-III non-small cell lung cancer (NSCLC), may have utility to...
5.
Vahidian F, Lamaze F, Bouffard C, Coulombe F, Gagne A, Blais F, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398098
Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancers (NSCLCs) treatment, but only 20-30% of patients benefit from these treatments. Currently, PD-L1 expression in tumor cells is the only...
6.
Dia A, Ebrahimpour L, Yolchuyeva S, Tonneau M, Lamaze F, Orain M, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254838
Background: Recent advances in cancer biomarker development have led to a surge of distinct data modalities, such as medical imaging and histopathology. To develop predictive immunotherapy biomarkers, these modalities are...
7.
Yolchuyeva S, Giacomazzi E, Tonneau M, Ebrahimpour L, Lamaze F, Orain M, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568646
Background: Immune checkpoint inhibitors (ICIs) are a great breakthrough in cancer treatments and provide improved long-term survival in a subset of non-small cell lung cancer (NSCLC) patients. However, prognostic and...
8.
Harwood M, Alves I, Edgington H, Agbessi M, Bruat V, Soave D, et al.
Sci Adv
. 2022 May;
8(19):eabl3819.
PMID: 35559670
How the genetic composition of a population changes through stochastic processes, such as genetic drift, in combination with deterministic processes, such as selection, is critical to understanding how phenotypes vary...
9.
Houle A, Gibling H, Lamaze F, Edgington H, Soave D, Fave M, et al.
Genome Res
. 2018 Oct;
28(11):1611-1620.
PMID: 30341163
The binding of PRDM9 to chromatin is a key step in the induction of DNA double-strand breaks associated with meiotic recombination hotspots; it is normally expressed solely in germ cells....
10.
Fave M, Lamaze F, Soave D, Hodgkinson A, Gauvin H, Bruat V, et al.
Nat Commun
. 2018 Mar;
9(1):827.
PMID: 29511166
Uncovering the interaction between genomes and the environment is a principal challenge of modern genomics and preventive medicine. While theoretical models are well defined, little is known of the G ...